New drug IDP-001 takes on advanced cancers in early trial

NCT ID NCT07602842

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests an experimental drug called IDP-001 in people with advanced or metastatic solid tumors, including certain lung, head and neck, and other cancers. The trial has two phases: first to check safety and find the right dose, then to see if the drug can shrink tumors. About 132 participants will receive IDP-001 by IV infusion.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
IDP-001 (an experimental drug given by IV infusion)
What this could lead to
If successful, this could point toward a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong
This is an early phase 1/2 trial with only 132 participants, so it is primarily testing safety and dosing. The drug may not shrink tumors or may cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hackensack Meridian - John Theurer Cancer Center

    Edison, New Jersey, 08837, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.